SI2726460T1 - Spojine za zdravljenje zasvojenosti - Google Patents
Spojine za zdravljenje zasvojenostiInfo
- Publication number
- SI2726460T1 SI2726460T1 SI201230340T SI201230340T SI2726460T1 SI 2726460 T1 SI2726460 T1 SI 2726460T1 SI 201230340 T SI201230340 T SI 201230340T SI 201230340 T SI201230340 T SI 201230340T SI 2726460 T1 SI2726460 T1 SI 2726460T1
- Authority
- SI
- Slovenia
- Prior art keywords
- addiction
- compounds
- treatment
- Prior art date
Links
- 206010012335 Dependence Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503923P | 2011-07-01 | 2011-07-01 | |
| EP12735394.4A EP2726460B1 (en) | 2011-07-01 | 2012-06-29 | Compounds for the treatment of addiction |
| PCT/US2012/044809 WO2013006400A1 (en) | 2011-07-01 | 2012-06-29 | Compounds for the treatment of addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2726460T1 true SI2726460T1 (sl) | 2015-11-30 |
Family
ID=46513858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201230340T SI2726460T1 (sl) | 2011-07-01 | 2012-06-29 | Spojine za zdravljenje zasvojenosti |
Country Status (32)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
| KR20140033377A (ko) | 2011-05-10 | 2014-03-18 | 길리애드 사이언시즈, 인코포레이티드 | 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물 |
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| WO2014160185A2 (en) | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
| CA2931550C (en) * | 2013-12-13 | 2023-09-26 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| US10077669B2 (en) | 2014-11-26 | 2018-09-18 | United Technologies Corporation | Non-metallic engine case inlet compression seal for a gas turbine engine |
| US10289971B2 (en) | 2015-02-13 | 2019-05-14 | Atlassian Pty Ltd | Issue and trigger rebalancing in a ranked issue management system |
| RS63872B1 (sr) | 2016-08-19 | 2023-02-28 | Univ Bristol | Derivati citizina za lečenje zavisnosti |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CA3077606A1 (en) * | 2017-10-16 | 2019-04-25 | Amygdala Neurosciences, Inc. | Combination therapy for preventing addiction |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| KR102551319B1 (ko) | 2018-05-14 | 2023-07-05 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 억제제 |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| EP3829562A1 (en) * | 2018-07-27 | 2021-06-09 | Amygdala Neurosciences, Inc. | Combination therapy for nicotine addiction |
| WO2020076974A1 (en) * | 2018-10-12 | 2020-04-16 | Amygdala Neurosciences, Inc. | Addiction treatment of an alcohol-consuming patient population |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| WO2023244574A1 (en) * | 2022-06-14 | 2023-12-21 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
| US20230399299A1 (en) | 2022-06-14 | 2023-12-14 | Amygdala Neurosciences, Inc. | Aldh-2 inhibitor compounds and methods of use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5204369A (en) | 1991-07-01 | 1993-04-20 | The Endowment For Research In Human Biology | Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse |
| AU3899199A (en) * | 1998-05-12 | 1999-11-29 | Endowment for Research in Human Biology, Inc., The | Methods and assays useful in the treatment of alcohol dependence or alcohol abuse |
| CN1671373A (zh) | 2002-06-27 | 2005-09-21 | 人类生物研究基金公司 | 用于抑制aldh的化合物 |
| JP2004182657A (ja) * | 2002-12-04 | 2004-07-02 | Eisai Co Ltd | Ｈｄｌレベル上昇促進剤 |
| US20080004260A1 (en) | 2006-06-29 | 2008-01-03 | Transcept Pharmaceuticals, Inc. | Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions |
| KR20090033417A (ko) | 2006-07-27 | 2009-04-03 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 중독의 치료에서의 ａｌｄｈ-2 저해제 |
| US20080207610A1 (en) | 2006-07-27 | 2008-08-28 | Jeff Zablocki | Aldh-2 inhibitors in the treatment of addiction |
| US8158810B2 (en) | 2006-07-27 | 2012-04-17 | Gilead Sciences, Inc. | ALDH-2 inhibitors in the treatment of addiction |
| US20110105602A2 (en) | 2007-03-08 | 2011-05-05 | Daria Mochly-Rosen | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof |
| AU2008348372A1 (en) | 2008-01-24 | 2009-07-30 | Gilead Palo Alto, Inc. | ALDH-2 inhibitors in the treatment of addiction |
| RU2531272C2 (ru) | 2008-05-01 | 2014-10-20 | Вайтаи Фармасьютиклз, Инк. | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 |
| US8354435B2 (en) | 2008-09-08 | 2013-01-15 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase activity and methods of use thereof |
| CN102202669A (zh) * | 2008-10-28 | 2011-09-28 | 利兰·斯坦福青年大学托管委员会 | 醛脱氢酶调节剂及其使用方法 |
| UY33469A (es) * | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
| TWI567061B (zh) * | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
-
2012
- 2012-06-26 TW TW101122794A patent/TWI567061B/zh not_active IP Right Cessation
- 2012-06-27 UY UY0001034165A patent/UY34165A/es not_active Application Discontinuation
- 2012-06-28 AR ARP120102331A patent/AR086792A1/es not_active Application Discontinuation
- 2012-06-29 US US13/537,536 patent/US8558001B2/en active Active
- 2012-06-29 BR BR112014000033A patent/BR112014000033A2/pt active Search and Examination
- 2012-06-29 SG SG10201605355RA patent/SG10201605355RA/en unknown
- 2012-06-29 MD MDA20140009A patent/MD4436B1/ro not_active IP Right Cessation
- 2012-06-29 ES ES15184883.5T patent/ES2656716T3/es active Active
- 2012-06-29 PH PH1/2013/502674A patent/PH12013502674A1/en unknown
- 2012-06-29 AU AU2012279332A patent/AU2012279332B2/en not_active Ceased
- 2012-06-29 MX MX2013014938A patent/MX337611B/es active IP Right Grant
- 2012-06-29 PL PL12735394T patent/PL2726460T3/pl unknown
- 2012-06-29 CA CA2840763A patent/CA2840763C/en active Active
- 2012-06-29 KR KR1020147002302A patent/KR101664915B1/ko not_active Expired - Fee Related
- 2012-06-29 CN CN201280032944.6A patent/CN103635460B/zh not_active Expired - Fee Related
- 2012-06-29 PT PT127353944T patent/PT2726460E/pt unknown
- 2012-06-29 KR KR1020167023967A patent/KR20160106207A/ko not_active Withdrawn
- 2012-06-29 WO PCT/US2012/044809 patent/WO2013006400A1/en not_active Ceased
- 2012-06-29 UA UAA201314148A patent/UA109199C2/ru unknown
- 2012-06-29 SI SI201230340T patent/SI2726460T1/sl unknown
- 2012-06-29 EA EA201391635A patent/EA025573B1/ru not_active IP Right Cessation
- 2012-06-29 JP JP2014519122A patent/JP5943998B2/ja not_active Expired - Fee Related
- 2012-06-29 DK DK15184883.5T patent/DK2993170T3/da active
- 2012-06-29 ES ES12735394.4T patent/ES2553829T3/es active Active
- 2012-06-29 EP EP12735394.4A patent/EP2726460B1/en active Active
- 2012-06-29 AP AP2013007282A patent/AP3544A/xx active
- 2012-06-29 EP EP15184883.5A patent/EP2993170B1/en active Active
- 2012-06-29 PE PE2013002811A patent/PE20141067A1/es not_active Application Discontinuation
-
2013
- 2013-03-08 US US13/791,422 patent/US8575353B2/en active Active
- 2013-08-13 US US13/966,029 patent/US9000015B2/en active Active
- 2013-11-28 ZA ZA2013/08977A patent/ZA201308977B/en unknown
- 2013-12-13 CR CR20130659A patent/CR20130659A/es unknown
- 2013-12-16 CL CL2013003597A patent/CL2013003597A1/es unknown
- 2013-12-18 EC ECSP13013087 patent/ECSP13013087A/es unknown
- 2013-12-18 CO CO13295408A patent/CO6821964A2/es active IP Right Grant
- 2013-12-30 MA MA36629A patent/MA35404B1/fr unknown
-
2014
- 2014-01-26 IL IL230657A patent/IL230657B/en active IP Right Grant
-
2015
- 2015-03-16 US US14/659,042 patent/US9610299B2/en not_active Expired - Fee Related
-
2017
- 2017-03-31 US US15/476,569 patent/US9987295B2/en active Active
-
2018
- 2018-05-08 US US15/974,171 patent/US10507215B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP3544A (en) | Compounds for the treatment of addiction | |
| IL231836A0 (en) | The vehicle for treating the siege | |
| SG2014014724A (en) | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS | |
| GB2509659B (en) | Process for the 3-O-demethylation of morphinan compounds | |
| SG11201400939YA (en) | Process for the preparation of methoxymelonal | |
| IL231593B (en) | Buprenorphine for the treatment of acute suicidality | |
| IL226677A (en) | Beta-amyloid production compounds | |
| IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
| EP2704731A4 (en) | TREATMENT OF AVIAN ORIGIN | |
| GB201119690D0 (en) | Process for the preparation of compounds | |
| PL393916A1 (pl) | Sposób wytwarzania związków karbapenamowych | |
| ZA201309732B (en) | Process for the preparation of dexlansoprazole | |
| GB201102283D0 (en) | Treatment | |
| HK1197236B (en) | Compounds for the treatment of addiction | |
| GB201119533D0 (en) | Compounds for the treatment of neoplasia | |
| PL394420A1 (pl) | Sposób wytwarzania dilauroilofluoresceiny | |
| PL394378A1 (pl) | Sposób otrzymywania E-2-amino-4-nitrostilbenów | |
| GB201106981D0 (en) | Compounds for the treatment of clostridium difficle-associated disease | |
| GB201102269D0 (en) | Treatment | |
| GB201102266D0 (en) | Treatment | |
| GB201102267D0 (en) | Treatment | |
| GB201102273D0 (en) | Treatment | |
| GB201102263D0 (en) | Treatment | |
| GB201102274D0 (en) | Treatment | |
| GB201102265D0 (en) | Treatment |